The Mitogen Activated Protein Kinase 14 pipeline drugs market research report outlays comprehensive information on the Mitogen Activated Protein Kinase 14 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mitogen Activated Protein Kinase 14 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Respiratory, and Immunology which include the indications Pancreatic Cancer, Solid Tumor, Alzheimer’s Disease, Dementia, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Inflammation, and Cytokine Release Syndrome (Cytokine Storm). It also reviews key players involved in Mitogen Activated Protein Kinase 14 targeted therapeutics development with respective active and dormant or discontinued products.
The Mitogen Activated Protein Kinase 14 pipeline targets constitutes close to 18 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 6, 2, 5, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
Mitogen Activated Protein Kinase 14 overview
Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.
For a complete picture of Mitogen Activated Protein Kinase 14’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
